Clinical Trial Update: Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update reports on the efficacy and safety of combining glofitamab with GemOx (gemcitabine plus oxaliplatin) in patients with refractory diff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• GemOx (gemcitabine + oxaliplatin) (gemcitabine and oxaliplatin)
• Glofitamab (glofitamab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING